| Catalog No. | HF610016 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG4-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | Stuart factor, Stuart-Prower factor, Coagulation factor X, F10, Plasma thromboplastin component, F9, Christmas factor, Coagulation factor IX, PTC |
|---|
| Concentration | 1.16mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | P00742, P00740 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -600°C. |
|---|
| Alternate Names | Bispecific,ACE-910,RG6013,hBS910,CAS:1610943-06-0 |
|---|
| Background | Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
